Bendamustine/mitoxantrone/rituximab: A short remission induction chemoimmunotherapy for elderly patients with relapsed or refractory chronic lymphocytic leukemia

Leukemia and Lymphoma

Volumn 50, Issue 9, 2009, Pages 1468-1474

  Weide, Rudolf ^a   Mergenthaler, Ulrike ^b   Friesenhahn, Vera ^b   Kleboth, Kristina ^b   Heymanns, Jochen ^a   Thomalla, Jörg ^a   Köppler, Hubert ^a  

^a Praxisklinik für Hämatologie und Onkologie ^*  (Germany)

^b Institut fur Versorgungsforschung in der Onkologie   (Germany)

Author keywords

BMR; chemoimmunotherapy; CLL; elderly; relapsed

Indexed keywords

BENDAMUSTINE; MITOXANTRONE; RITUXIMAB; ANTINEOPLASTIC AGENT; CHLORMETHINE DERIVATIVE; MONOCLONAL ANTIBODY;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD TOXICITY; BRADYCARDIA; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RELAPSE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; FEMALE; GRANULOCYTOPENIA; HOSPITALIZATION; HUMAN; LEUKEMIA REMISSION; LEUKOPENIA; LYMPHOCYTOPENIA; MALE; NAUSEA AND VOMITING; PRIORITY JOURNAL; RETROSPECTIVE STUDY; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING; DRUG EFFECT; DRUG RESISTANCE; EVALUATION; IMMUNOTHERAPY; METHODOLOGY; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOLOGY; RECURRENT DISEASE; REMISSION; SALVAGE THERAPY;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; IMMUNOTHERAPY; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; MITOXANTRONE; NITROGEN MUSTARD COMPOUNDS; RECURRENCE; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SALVAGE THERAPY;

EID: 77953470382     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190903166330     Document Type: Article

References (19)

1. Leoni LM, Bailey B, Reifert J, et al. Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clin Cancer Res 2008;14:309-317. (Pubitemid 351378007)
2. Bremer K. High rates of long lasting remissions after 5-day bendamustine chemotherapy cycles in pre-treated low-grade non-Hodgkin's lymphomas. J Cancer Res Clin Oncol 2002;128:603-609. (Pubitemid 35435557)
3. Christian BA. Antibody therapy for chronic lymphocytic leukemia. Semin Hematol 2008;45:95-103. (Pubitemid 351434408)
4. Keating MJ, O'Brien S, Albitar M, et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophoshamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 2005;20:4079-4088. (Pubitemid 46211313)
5. Wierda W, O'Brien S, Wen S, et al. Chemoimmunotherapy with fludarabine, cyclophosphamide and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol 2005;20:4070-4078. (Pubitemid 46211312)
6. Weide R, Heymanns J, Gores A, et al. Bendamustine, mitoxantrone and rituximab (BMR): a new effective regimen for refractory or relapsed indolent lymphomas. Leuk Lymphoma 2002;43:327-331. (Pubitemid 34202111)
7. Weide R, Pandorf A, Heymanns J, et al. Bendamustine/mitoxantrone/ rituximab (BMR): a very effective, well tolerated outpatient chemoimmunotherapy for relapsed and refractory CD-20-positive indolent malignancies. Final results of a pilot study. Leuk Lymphoma 2004;48:1299-1306.
8. Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined comorbidity index. J Clin Epidemiol 1994;47:1245-1251. (Pubitemid 24361532)
9. Cheson BD, Bennett JM, Grever M, et al. National Cancer Institute-Sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996;87:4990-4997. (Pubitemid 26189840)
10. Hallek M, Fingerle-Rowson G, Fink AM, et al. Immunochemotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) versus fludarabine and cyclophosphamide (FC) improves response rates and progression-free survival (PFS) of previously untreated patients (pts) with advanced chronic lymphocytic leukemia (CLL). Blood 2008;112; Abstract 325.
11. Robak T, Moiseev SI, Dmoszynska A, et al. Rituximab, fludarabine, and cyclophosphamide (R-FC) prologs progression free survival in relapsed or refractory chronic lymphocytic leukemia (CLL) compared with FC Alone: final results from the International Randomized Phase III REACH Trial. Blood 2008;112:Abstract 1.
12. Chanan-Khan A, Miller KC, Musial L, et al. Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukaemia: results of a phase II study. J Clin Oncol 2006;24:5343-5349. (Pubitemid 46623164)
13. Lin TS, Heerema NA, Lozanski G, et al. Flavopiridol (Alvocidib) induces durable responses in relapsed chronic lymphocytic leukaemia (CLL) patients with high-risk cytogenetic abnormalities. Blood 2008;112:Abstract 46.
14. Schwänen C, Hecker T, Hübinger G, et al. In vitro evaluation of bendamustine induced apoptosis in B-chronic lymphocytic leukemia. Leukemia 2002;16:2096-2105. (Pubitemid 35203454)
15. Knauf WU, Lissichkov T, Aldaoud A, et al. Bendamustine versus chlorambucil in treatment-näive patients with B-cell chronic lymphocytic leukemia (B-CLL): results of an International phase III study. Blood 2007;110:Abstract 2043.
16. Aivado M, Schulte K, Henze L, et al. Bendamustine in the treatment of chronic lymphocytic leukemia: results and future perspectives. Semin Oncol 2002;29(4 Suppl 13):19-22. (Pubitemid 34857893)
17. Bergmann MA, Goebeler ME, Herold M, et al. Efficacy of bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia: results of a Phase I/II study of the German CLL Study Group. Haematologica 2005;90:1357-1364. (Pubitemid 41503651)
18. Chow KU, Sommerlad WD, Boehrer S, et al. Anti-CD20 antibody (IDEC-C2B8 rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement and caspases. Haematologica 2002;87:33-43. (Pubitemid 34101111)
19. Fischer K, Stilgenbauer S, Schweighofer CD, et al. Bendamustine in combination with rituximab (BR) for patients with relapsed chronic lymphocytic leukemia (CLL): a multicentre phase II trial of the German CLL Study Group (GCLLSG). Blood 2008;112:Abstract 330.